Document:

Exhibit
4.6

 

RIGHTS
AGREEMENT

 

This
Rights Agreement (this “Agreement”) is made as of November 9, 2020 between Edoc Acquisition Corp., a Cayman Islands
exempted company, with offices at 7612 Main Street Fishers, Suite 200, Victor, NY 14564 (“Company”), and Continental
Stock Transfer & Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New
York, New York 10004 (“Rights Agent”).

 

WHEREAS,
the Company has received binding commitments from American Physicians LLC, a Delaware limited liability company (the “Sponsor”),
and from I-Bankers Securities, Inc. (the “Representative”) to purchase up to an aggregate of 479,000 units, each unit
(“Unit”) comprised of one Class A ordinary share of the Company, $0.0001 par value per share (“Class A Class
A Ordinary Share ”), one warrant to purchase one-half of one Class A Ordinary Share (“Warrant”) and one right
to receive one-tenth of one Class A Ordinary Share upon the happening of the triggering event described herein (“Right”),
and in connection therewith, will issue and deliver up to an aggregate of 479,000 Rights as part of such Units upon consummation
of such private placement (the “Private Offering”); and

 

WHEREAS,
the Company is engaged in a public offering (“Public Offering”) of Units and, in connection therewith, will issue
and deliver up to 10,350,000 Rights to the public investors; and

 

WHEREAS,
in order to finance the Company’s transaction costs in connection with an intended initial Business Combination (as defined
in the Company’s Amended and Restated Memorandum and Articles of Association), the Sponsor or an affiliate of the Sponsor
or certain of the Company’s executive officers and directors may loan to the Company funds as may be required, of which
up to $1,500,000 of such loans may be convertible into up to an additional 150,000 Units, and in connection therewith, will issue
and deliver up to an aggregate of 150,000 Rights; and

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-1,
File No. 333-248819 (“Registration Statement”), and related Prospectus (“Prospectus”) for the registration,
under the Securities Act of 1933, as amended (“Act”), of, among other securities, the Rights and the Class A Ordinary
Shares issuable to the holders of the Rights; and

 

WHEREAS,
the Company desires the Rights Agent to act on behalf of the Company, and the Rights Agent is willing to so act, in connection
with the issuance, registration, transfer and exchange of the Rights; and

 

WHEREAS,
the Company desires to provide for the form and provisions of the Rights, the terms upon which they shall be issued, and the respective
rights, limitation of rights, and immunities of the Company, the Rights Agent, and the holders of the Rights; and

 

WHEREAS,
all acts and things have been done and performed which are necessary to make the Rights, when executed on behalf of the Company
and countersigned by or on behalf of the Rights Agent, as provided herein, the valid, binding and legal obligations of the Company,
and to authorize the execution and delivery of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment
of Rights Agent. The Company hereby appoints the Rights Agent to act as agent for the Company for the Rights, and the Rights
Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in
this Agreement.

 

2. Rights.

 

2.1.
 Form of Right. Each Right shall be issued in registered form only, shall
be in substantially the form of Exhibit A hereto, the provisions of which are incorporated herein and shall be signed by, or bear
the facsimile signature of, the Chairman of the Board or Chief Executive Officer and the Secretary of the Company and shall bear
a facsimile of the Company’s seal. In the event the person whose facsimile signature has been placed upon any Right shall
have ceased to serve in the capacity in which such person signed the Right before such Right is issued, it may be issued with
the same effect as if he or she had not ceased to be such at the date of issuance.

 

    

     

    

 

2.2. Effect
of Countersignature. Unless and until countersigned by the Rights Agent pursuant to this Agreement, a Right shall be invalid
and of no effect and may not be exchanged for Class A Ordinary Shares.

 

2.3. Registration.

 

2.3.1. Right
Register. The Rights Agent shall maintain books (“Right Register”) for the registration of original issuance and
the registration of transfer of the Rights. Upon the initial issuance of the Rights, the Rights Agent shall issue and register
the Rights in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions
delivered to the Rights Agent by the Company.

 

2.3.2. Registered
Holder. Prior to due presentment for registration of transfer of any Right, the Company and the Rights Agent may deem and
treat the person in whose name such Right shall be registered upon the Right Register (“registered holder”) as the
absolute owner of such Right and of each Right represented thereby (notwithstanding any notation of ownership or other writing
on the Right Certificate made by anyone other than the Company or the Rights Agent), for the purpose of the exchange thereof,
and for all other purposes, and neither the Company nor the Rights Agent shall be affected by any notice to the contrary.

 

2.4. Detachability of Rights. The securities comprising the Units, including
the Rights, will not be separately transferable until the earlier to occur of: (i) the 52nd day following the
date of the Prospectus or (ii) the announcement by the Representative, as representative of the underwriters in the Public Offering,
of its intention to allow separate earlier trading (the “Detachment Date”), except that in no event will the securities
comprising the Units be separately tradeable until the Company files a Current Report on Form 8-K with the SEC which includes
an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Public Offering including the proceeds
received by the Company from the exercise of the over-allotment option, if the over-allotment option is exercised by the date
thereof and the Company issues a press release and files a Current Report on Form 8-K with the SEC announcing when such separate
trading shall begin. Upon the Detachment Date, the Units will no longer trade, and each holder of Units will become, without any
action by such holder, the holder of that number of shares of Class A Ordinary Shares, warrants and Rights comprising the Units
held by such holder.

 

3.
 Terms and Exchange of Rights

 

3.1. Rights. Each Right shall entitle the holder thereof to receive one-tenth
of one Class A Ordinary Share upon the happening of an Exchange Event (defined below). No additional consideration shall be paid
by a holder of Rights in order to receive his, her or its Class A Ordinary Shares upon an Exchange Event as the purchase price
for such Class A Ordinary Shares has been included in the purchase price for the Units. In no event will the Company be required
to net cash settle the Rights or issue fractional Class A Ordinary Shares.

 

3.2. Exchange
Event. An “Exchange Event” shall occur upon the Company’s consummation of an initial Business Combination
(as defined in the Company’s Amended and Restated Memorandum and Articles of Association).

 

3.3. Exchange
of Rights.

 

3.3.1. Issuance
of Class A Ordinary Shares. As soon as practicable upon the occurrence of an Exchange Event, the Company shall direct holders
of the Rights to return their Rights Certificates to the Rights Agent. Upon receipt of a valid Rights Certificate, the Company
shall issue to the registered holder of such Right(s) the number of full Class A Ordinary Shares to which he, she or it is entitled,
registered in such name or names as may be directed by him, her or it and issue to such registered holder(s) a certificate or
book-entry position for the such shares. Notwithstanding the foregoing, or any provision contained in this Agreement to the contrary,
in no event will the Company be required to net cash settle the Rights. The Company shall not issue fractional shares upon exchange
of Rights. In the event that any holder would otherwise be entitled to any fractional share upon exchange of Rights, at the time
of an Exchange Event, the Company will instruct the Right Agent how any such entitlement will be addressed. To the fullest extent
permitted by the Company’s Amended and Restated Memorandum and Articles of Association the Company reserves the right to
deal with any such fractional entitlement at the relevant time in any manner permitted by the Act and the Amended and Restated
Memorandum and Articles of Association, which would include the rounding down of any entitlement to receive Class A Ordinary Shares
to the nearest whole share (and in effect extinguishing any fractional entitlement), or the holder being entitled to hold any
remaining fractional entitlement (without any share being issued) and to aggregate the same with any future fractional entitlement
to receive shares in the Company until the holder is entitled to receive a whole number. Any rounding down and extinguishment
may be done with or without any in lieu cash payment or other compensation being made to the holder of the relevant Rights, such
that value received on exchange of the Rights may be considered less than the value that the holder would otherwise expect to
receive.

 

    2

     

    

 

3.3.2. Valid
Issuance. All Class A Ordinary Shares issued upon an Exchange Event in conformity with this Agreement shall be validly issued,
fully paid and nonassessable.

 

3.3.3. Date
of Issuance. Each person in whose name any such certificate or book-entry position for Class A Ordinary Shares is issued shall
for all purposes be deemed to have become the holder of record of such shares on the date of the Exchange Event, irrespective
of the date of delivery of such certificate or entry of position.

 

3.3.4 Company
Not Surviving Following Exchange Event. Upon an Exchange Event in which the Company does not continue as the publicly held
reporting entity, the definitive agreement will provide for the holders of Rights to receive the same per share consideration
the holders of the Class A Ordinary Shares will receive in such transaction, for the number of shares such holder is entitled
to pursuant to Section 3.3.1 above. If the Company does not continue as the publicly held reporting entity upon an Exchange Event,
each holder of a Right will be required to affirmatively convert his/her or its rights in order to receive the 1/10 share underlying
each right (without paying any additional consideration) upon consummation of the Exchange Event. In such a case, each holder
of a Right will be required to indicate his, her or its election to convert the Rights into underlying shares as well as to return
the original certificates evidencing the Rights to the Company.

 

3.5 Duration
of Rights. If an Exchange Event does not occur within the time period set forth in the Company’s Amended and Restated
Memorandum and Articles of Association, as the same may be amended from time to time, the Rights shall expire and shall be worthless;
provided that for as long as any of the Rights sold in the Private Offering are held by the Representative or its designees or
affiliates, such Rights may not be exercised after five years from the effective date of the Registration Statement.

 

4.
 Transfer and Exchange of Rights.

 

4.1. Registration
of Transfer. The Rights Agent shall register the transfer, from time to time, of any outstanding Right upon the Right Register,
upon surrender of such Right for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate
instructions for transfer. Upon any such transfer, a new Right representing an equal aggregate number of Rights shall be issued
and the old Right shall be cancelled by the Rights Agent. The Rights so cancelled shall be delivered by the Rights Agent to the
Company from time to time upon request.

 

4.2. Procedure
for Surrender of Rights. Rights may be surrendered to the Rights Agent, together with a written request for exchange or transfer,
and thereupon the Rights Agent shall issue in exchange therefor one or more new Rights as requested by the registered holder of
the Rights so surrendered, representing an equal aggregate number of Rights; provided, however, that in the event that a Right
surrendered for transfer bears a restrictive legend and the new Rights to be issued will not bear a restrictive legend, the Rights
Agent shall not cancel such Right and issue new Rights in exchange therefor until the Rights Agent has received an opinion of
counsel for the Company stating that such transfer may be made and indicating no restrictive legend is required.

 

4.3. Fractional
Rights. The Rights Agent shall not be required to effect any registration of transfer or exchange which will result in the
issuance of a Right Certificate for a fraction of a Right.

 

4.4. Service Charges. No service charge shall be made for any exchange
or registration of transfer of Rights.

 

    3

     

    

 

4.5. Adjustments to Conversion Ratios. The number of Class A Ordinary
Shares that the holders of Rights are entitled to receive as a result of the occurrence of an Exchange Event shall be equitably
adjusted to reflect appropriately the effect of any share split, reverse share split, share dividend, reorganization, recapitalization,
reclassification, combination, exchange of shares or other like change with respect to the Class A Ordinary Shares occurring on
or after the date hereof and prior to the Exchange Event.

 

4.6. Right
Execution and Countersignature. The Rights Agent is hereby authorized to countersign and to deliver, in accordance with the
terms of this Agreement, the Rights required to be issued pursuant to the provisions of this Section 4, and the Company, whenever
required by the Rights Agent, will supply the Rights Agent with Rights duly executed on behalf of the Company for such purpose.

 

5.
 Other Provisions Relating to Rights of Holders of Rights.

 

5.1. No Rights as Shareholder. Until exchange of a Right for Class A Ordinary
Shares as provided for herein, a Right does not entitle the registered holder thereof to any of the rights of a shareholder of
the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights
to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors
of the Company or any other matter.

 

5.2. Lost,
Stolen, Mutilated, or Destroyed Rights. If any Right is lost, stolen, mutilated, or destroyed, the Company and the Rights
Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated
Right, include the surrender thereof), issue a new Right of like denomination, tenor, and date as the Right so lost, stolen, mutilated,
or destroyed. Any such new Right shall constitute a substitute contractual obligation of the Company, whether or not the allegedly
lost, stolen, mutilated, or destroyed Right shall be at any time enforceable by anyone.

 

5.3. Reservation of Class A Ordinary Shares. The Company shall at all
times reserve and keep available a number of its authorized but unissued Class A Ordinary Shares that will be sufficient to permit
the exchange of all outstanding Rights issued pursuant to this Agreement.

 

6. Concerning the Rights Agent and Other Matters.

 

6.1. Payment of Taxes. The Company will from time to time promptly pay
all taxes and charges that may be imposed upon the Company or the Rights Agent in respect of the issuance or delivery of Class
A Ordinary Shares upon the exchange of Rights, but the Company shall not be obligated to pay any transfer taxes in respect of
the Rights or such Class A Ordinary Shares.

 

6.2. Resignation,
Consolidation, or Merger of Rights Agent.

 

6.2.1. Appointment of Successor Rights Agent. The
Rights Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and
liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Rights Agent
becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Rights Agent
in place of the Rights Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been
notified in writing of such resignation or incapacity by the Rights Agent or by the holder of the Right (who shall, with such
notice, submit his, her or its Right for inspection by the Company), then the holder of any Right may apply to the Supreme Court
of the State of New York for the County of New York for the appointment of a successor Rights Agent at the Company’s cost.
Any successor Rights Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under
the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State
of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal
or state authority. After appointment, any successor Rights Agent shall be vested with all the authority, powers, rights, immunities,
duties, and obligations of its predecessor Rights Agent with like effect as if originally named as Rights Agent hereunder, without
any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Rights Agent shall execute
and deliver, at the expense of the Company, an instrument transferring to such successor Rights Agent all the authority, powers,
and rights of such predecessor Rights Agent hereunder; and upon request of any successor Rights Agent the Company shall make,
execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming
to such successor Rights Agent all such authority, powers, rights, immunities, duties, and obligations. 

 

    4

     

    

 

6.2.2. Notice of Successor Rights Agent. In the
event a successor Rights Agent shall be appointed, the Company shall give notice thereof to the predecessor Rights Agent and the
transfer agent for the Class A Ordinary Shares not later than the effective date of any such appointment.

 

6.2.3. Merger or Consolidation of Rights Agent.
Any corporation into which the Rights Agent may be merged or with which it may be consolidated or any corporation resulting from
any merger or consolidation to which the Rights Agent shall be a party shall be the successor Rights Agent under this Agreement
without any further act.

 

6.3. Fees
and Expenses of Rights Agent.

 

6.3.1. Remuneration. The Company agrees to pay the
Rights Agent reasonable remuneration for its services as such Rights Agent hereunder and will reimburse the Rights Agent upon
demand for all expenditures that the Rights Agent may reasonably incur in the execution of its duties hereunder.

 

6.3.2. Further
Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged,
and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Rights Agent for
the carrying out or performing of the provisions of this Agreement.

 

6.4. Liability
of Rights Agent.

 

6.4.1. Reliance
on Company Statement. Whenever in the performance of its duties under this Agreement, the Rights Agent shall deem it necessary
or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder,
such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively
proved and established by a statement signed by the Chief Executive Officer or Chief Financial Officer and delivered to the Rights
Agent. The Rights Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions
of this Agreement.

 

6.4.2. Indemnity.
The Rights Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. Subject to Section
6.6 below, the Company agrees to indemnify the Rights Agent and save it harmless against any and all liabilities, including judgments,
costs and reasonable counsel fees, for anything done or omitted by the Rights Agent in the execution of this Agreement except
as a result of the Rights Agent’s gross negligence, willful misconduct, or bad faith.

 

6.4.3. Exclusions.
The Rights Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or
execution of any Right (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any
covenant or condition contained in this Agreement or in any Right; nor shall it by any act hereunder be deemed to make any representation
or warranty as to the authorization or reservation of any Class A Ordinary Shares to be issued pursuant to this Agreement or any
Right or as to whether any Class A Ordinary Shares will when issued be valid and fully paid and nonassessable. 

 

6.5. Acceptance
of Agency. The Rights Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the
terms and conditions herein set forth.

 

    5

     

    

 

6.6
 Waiver. The Rights Agent hereby waives any right of set-off
or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account
(as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and
the Rights Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any
Claim against the Trust Account for any reason whatsoever.

 

7. Miscellaneous
Provisions.

 

7.1. Successors. All the covenants and provisions of this Agreement by
or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective successors and assigns.

 

7.2. Notices.
Any notice, statement or demand authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Right
to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail
or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is
filed in writing by the Company with the Rights Agent), as follows:

 

Edoc
Acquisition Corp.

7612
Main Street Fishers

Suite
200

Victor,
NY 14564

Attn:
Kevin Chen, Chief Executive Officer

 

Any
notice, statement or demand authorized by this Agreement to be given or made by the holder of any Right or by the Company to or
on the Rights Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail
or private courier service within five days after deposit of such notice, postage prepaid, addressed (until another address is
filed in writing by the Rights Agent with the Company), as follows:

 

Continental
Stock Transfer & Trust Company

One
State Street, 30th Floor

New
York, New York 10004

Attn:
Compliance Department

 

with
a copy to:

Ellenoff
Grossman & Schole, LLP

1345
Avenue of the Americas

New
York, NY 10105

Attn:
Barry Grossman, Esq

 

and

 

Schiff
Hardin LLP

901
K Street NW

Suite
700

Washington,
D.C. 20001

Attn:
Ralph V. De Martino, Esq.

 

 

and

 

Maples
and Calder

P.O.
Box 309, Ugland House

Grand
Cayman

KY1-1104

Cayman
Islands

Attn:
Matthew Gardner 

 and

 

I-Bankers
Securities Inc

535
5th Ave.

New
York, NY 10017

Attn:
Shelley Leonard, President

 

    6

     

    

 

7.3. Applicable Law and Exclusive Forum. The validity, interpretation,
and performance of this Agreement and of the Rights shall be governed in all respects by the laws of the State of New York. Subject
to applicable law, the Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any
way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court
for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive forum
for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that such
courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits
brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts
of the United States of America are the sole and exclusive forum.

 

Any
person or entity purchasing or otherwise acquiring any interest in the Rights shall be deemed to have notice of and to have consented
to the forum provisions in this Section 7.3. If any action, the subject matter of which is within the scope the forum provisions
above, is filed in a court other than a court located within the State of New York or the United States District Court for the
Southern District of New York (a “foreign action”) in the name of any Rights holder, such Rights holder shall be deemed
to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of New York or the
United States District Court for the Southern District of New York in connection with any action brought in any such court to
enforce the forum provisions (an “enforcement action”), and (y) having service of process made upon such Rights holder
in any such enforcement action by service upon such Rights holder’s counsel in the foreign action as agent for such Rights
holder.

 

7.4. Persons Having Rights under this Agreement. Nothing in this Agreement
expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon,
or give to, any person or corporation other than the parties hereto and the registered holders of the Rights and, for the purposes
of Sections 7.4 and 7.8 hereof, the Representative, any right, remedy, or claim under or by reason of this Agreement or of any
covenant, condition, stipulation, promise, or agreement hereof. The Representative shall be deemed to be a third-party beneficiary
of this Agreement with respect to Sections 7.4 and 7.8 hereof. All covenants, conditions, stipulations, promises, and agreements
contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto (and the Representative with respect
to the Sections 7.4 and 7.8 hereof) and their successors and assigns and of the registered holders of the Rights. The provisions
of this Section 7.4 may not be modified, amended or deleted without the prior written consent of the Representative.

 

7.5. Examination of the Right Agreement. A copy of this Agreement shall
be available at all reasonable times at the office of the Rights Agent in the Borough of Manhattan, City and State of New York,
for inspection by the registered holder of any Right. The Rights Agent may require any such holder to submit his, her or its Right
for inspection by it.

 

7.6. Counterparts.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

7.7. Effect
of Headings. The Section headings herein are for convenience only and are not part of this Agreement and shall not affect
the interpretation thereof.

 

7.8 Amendments.
This Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any
ambiguity, or of curing, correcting or supplementing any defective provision contained herein or adding or changing any other
provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and
that the parties deem shall not adversely affect the interest of the registered holders. All other modifications or amendments
shall require the written consent or vote of the registered holders of a majority of the then outstanding Rights. The provisions
of this Section 7.8 may not be modified, amended or deleted without the prior written consent of the Representative.

 

7.9 Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[Signature
Page Follows]

 

    7

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	EDOC
    ACQUISITION CORP.

 

	 	By:	/s/ Kevin Chen
	 	 	Name: Kevin Chen
	 	 	Title: Chief Executive Officer

 

	 	CONTINENTAL
    STOCK TRANSFER & 

TRUST COMPANY

 

	 	By:	 
	 	 	Name: 
	 	 	Title: 

 

[Signature
Page to Rights Agreement]

 

 

8Exhibit
10.1

 

November
9, 2020

 

Edoc
Acquisition Corp.

7612
Main Street Fishers

Suite
200

Victor,
NY 14564

Attn:
Kevin Chen, Chief Executive Officer

 

I-Bankers
Securities Inc

535
5th Ave

Suite 423

 

	 	Re:	Initial Public Offering

 

Gentlemen:

 

This
letter is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”)
entered into by and between Edoc Acquisition Corp., a Cayman Islands exempted company (the “Company”),
and I-Bankers Securities Inc., as Representative (the “Representative”) of the several Underwriters
named in Schedule A thereto (the “Underwriters”), relating to an underwritten initial public offering
(the “IPO”) of the Company’s units (the “Units”), each comprised of
one Class A ordinary share, $0.0001 par value per share, of the Company (the “Class A Ordinary Shares”)
and one redeemable warrant (the “Warrant”) to purchase one-half of one Class A Ordinary Share and one
right to receive one-tenth (1/10) of one Class A Ordinary Share upon the consummation of the Company’s initial business
combination (the “Right”). Certain capitalized terms used herein are defined in paragraph 17 hereof.

 

In
order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the IPO, and in
recognition of the benefit that such IPO will confer upon the undersigned as a shareholder or officer or director of the Company,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby
agrees with the Company as follows:

 

1.
 If the Company solicits approval of its shareholders of a Business Combination (as defined below), the undersigned will
vote all Ordinary Shares beneficially owned by him, her or it, whether acquired before, in or after the IPO, or whether such Ordinary
Shares are underlying the Private Units, in favor of such Business Combination.

 

2.
 (a) In the event that the Company fails to consummate a Business Combination within the time period set forth in the Company’s
Amended and Restated Memorandum and Articles of Association, as the same may be amended from time to time, the undersigned shall
take all reasonable steps to (i) cause the Trust Fund to be liquidated and distributed to the holders of IPO Shares and (ii) cause
the Company to liquidate as soon as reasonably practicable.

 

(b)
The undersigned hereby waives any and all right, title, interest or claim of any kind (“Claim”) in,
or, with respect to his, her or its Insider Shares or Private Units, to any distribution of, the Trust Fund. The undersigned hereby
waives any Claim the undersigned may have in the future as a result of, or arising out of, any contracts or agreements with the
Company and will not seek recourse against the Trust Fund for any reason whatsoever. The undersigned acknowledges and agrees that
there will be no distribution from the Trust Fund with respect to any Warrants, which will terminate on the Company’s liquidation.

 

(c)
In the event of the liquidation of the Trust Fund, American Physicians LLC (“Sponsor”) agrees to indemnify
and hold harmless the Company against any and all loss, liability, claims, damage and expense whatsoever (including, but not limited
to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether
pending or threatened, or any claim whatsoever) which the Company may become subject as a result of any claim by any vendor or
other person who is owed money by the Company for services rendered or products sold to or contracted for the Company, or by any
target business with which the Company has discussed entering into a transaction agreement, but only to the extent necessary to
ensure that such loss, liability, claim, damage or expense does not reduce the amount of funds in the Trust Fund to below $10.17
per IPO Share; provided that such indemnity shall not apply if such vendor or other person executes a waiver
of any and all rights to seek access to the Trust Account and except as to claims under the Company’s indemnity of the underwriters
of the IPO against certain liabilities.

 

     

     

    

 

3.
 (a) The Initial Shareholders agree that they shall not Transfer any Insider Shares: (x) with respect to 50% of its Insider
Shares, until the earlier of (i) six (6) months after the date of the consummation of the Business Combination or (ii) the date
on which the closing price of the Ordinary Shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends,
reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the Business
Combination; and (y) with respect to the remaining 50% of their Insider Shares, six (6) months after the date of the consummation
of the Business Combination, or earlier, in either case, if, subsequent to the Business Combination, the Company consummates a
subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders
having the right to exchange their Ordinary Shares for cash, securities or other property (the “Founder Shares Lock-up
Period”).

 

(b)
The Sponsor and each Insider agrees that it, he or she shall not effectuate any Transfer of securities issued or issuable upon
the exercise of the Private Units or their underlying securities until 30 days after the completion of the Business Combination
(the “Private Units Lock-up Period” and together with the Founder Shares Lock-up Period, the “Lock-up
Periods”).

 

(c)
Notwithstanding the provisions set forth in paragraphs 3(a) and (b), Transfers of the Insider Shares, securities issued or issuable
upon the exercise of the Private Units or their underlying securities, and that are held by the Sponsor, any Insider or any of
their permitted transferees (that have complied with this paragraph 3(c)), are permitted: (1) to any persons (including their
affiliates and shareholders) participating in the private placement of the Private Units, officers, directors, shareholders, employees
and members of the Sponsor and its affiliates, (2) amongst insiders or to the Company’s officers, directors and employees,
(3) if a holder is an entity, as a distribution to its, partners, shareholders or members upon its liquidation, (4) by bona fide
gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s
immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant
to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of
the Company’s securities, (8) by private sales at prices no greater than the price at which the applicable securities were
originally purchased or (9) to the Company for no value for cancellation in connection with the consummation of the Business Combination,
in each case (except for clause 9) where the transferee agrees to the terms of this letter agreement and by the same agreements
entered into by the Sponsor with respect to such securities.

 

(d)
The Sponsor hereby agrees to enter into an agreement in accordance with the guidelines of Rule 10b5-1 under the Exchange Act to
place limit orders, through an independent broker-dealer registered under Section 15 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) which is not affiliated with the Company nor part of the underwriting or
selling group in connection with the IPO, to purchase an aggregate of up to 3,750,000 of the Company’s Rights in the open
market at market prices, and not to exceed $0.20 per Right, during the period commencing on the later of (i) the date separate
trading of the Rights commences or (ii) sixty calendar days after the end of the “restricted period” under Regulation
M, continuing until the date that is the earlier of (a) twelve (12) months from the date of the prospectus filed in connection
with the IPO and (b) the date that the Company announces that it has entered into a definitive agreement in connection with a
Business Combination, or earlier in certain circumstances as described in the limit order agreement (the “Buyback
Period”). The limit orders will require the Sponsor to purchase any Rights offered for sale (and not purchased by
another investor) at or below a price of $0.20, until the earlier of (x) the expiration of the Buyback Period or (y) the date
such purchases reach 3,750,000 Rights in total. The Sponsor will not have any discretion or influence with respect to such purchases
and will not be able to sell or transfer any Rights purchased in the open market pursuant to such agreements. It is intended that
the broker’s purchase obligation will be subject to applicable law, including Regulation M under the Exchange Act, which
may prohibit or limit purchases pursuant to the limit order agreement in certain circumstances.

 

4.
 [Intentionally Omitted].

 

    2

     

    

 

5.
 In order to minimize potential conflicts of interest which may arise from multiple affiliations, the undersigned directors
and officers of the Company agree to present to the Company for its consideration, prior to presentation to any other person or
entity, any suitable opportunity to acquire a target business, until the earlier of the consummation by the Company of a Business
Combination or the liquidation of the Company, subject to any pre-existing fiduciary and contractual obligations the undersigned
directors and officers might have.

 

6.
 The undersigned acknowledges and agrees that prior to entering into a Business Combination with a target business that is
affiliated with any Insiders of the Company or their affiliates, such transaction must be approved by a majority of the Company’s
disinterested independent directors and the Company must obtain an opinion from an independent investment banking firm or independent
accounting firm that such Business Combination is fair to the Company’s unaffiliated shareholders from a financial point
of view.

 

7.
 Neither the undersigned, any member of the family of the undersigned, nor any affiliate of the undersigned will be entitled
to receive and will not accept any compensation or other cash payment for services rendered prior to, or in order to effectuate,
the consummation of the Business Combination; provided that the Company shall be allowed to (i) repay working
capital loans made by the undersigned or its affiliates to the Company in cash upon consummation of the Business Combination or,
at the undersigned’s discretion, with respect to up to an aggregate of $1,500,000 of working capital loans from all lenders,
by converting such loans into Private Units at a price of $10.00 per Private Unit, as more fully described in the Registration
Statement, (ii) repay non-interest bearing loans and advances in an aggregate amount of $177,591 made to the Company by the Initial
Shareholders to cover the IPO expenses, (iii) pay $10,000 per month to the Sponsor for office space and related services, and
(iv) reimburse the undersigned and any affiliate of the undersigned for their out-of-pocket expenses incurred in connection with
identifying, investigating and consummating a Business Combination.

 

8.
 Neither any undersigned officer or director, any member of the family of any undersigned officer or director, nor any affiliate
of any undersigned officer or director will be entitled to receive or accept a finder’s fee or any other compensation in
the event any undersigned officer or director, any member of the family of any undersigned officer or director or any affiliate
of any undersigned officer or director originates a Business Combination.

 

9.
 The undersigned officers and directors agree to be the officers and directors of the Company until the earlier of the consummation
by the Company of a Business Combination, the liquidation of the Company or such officer or director is officially replaced by
the Company’s board of directors. The undersigned officers’ and directors’ biographical information previously
furnished to the Company and the Representative is true and accurate in all material respects, does not omit any material information
with respect to the officers’ and directors’ biography and contains all of the information required to be disclosed
pursuant to Item 401 of Regulation S-K, promulgated under the Securities Act of 1933, as amended (the “Securities
Act”). Each of the undersigned officers’ and directors’ FINRA Questionnaire previously furnished to
the Company and the Representative is true and accurate in all material respects.

 

10. Each
of the undersigned represents and warrants that:

 

(a)
He, she or it has never had a petition under the federal bankruptcy laws or any state or foreign insolvency law been filed by
or against (i) him, her or it, or any partnership in which he, she or it was a general partner at or within two years before the
time of filing; or (ii) (to the extent the undersigned is an individual) any corporation or business association of which he or
she was an executive officer at or within two years before the time of such filing;

 

(b)
He, she or it has never had a receiver, fiscal agent or similar officer been appointed by a court for his or her business or property,
or any such partnership;

 

(c)
He, she, or it has never been convicted of fraud in a civil or criminal proceeding;

 

(d)
He, she, or it has never been convicted in a criminal proceeding or named the subject of a pending criminal proceeding (excluding
traffic violations and minor offenses);

 

    3

     

    

 

(e)
He, she, or it has never been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of
any court of competent jurisdiction, permanently or temporarily enjoining or otherwise limiting him from (i) acting as a futures
commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction
merchant, any other person regulated by the Commodity Futures Trading Commission (“CFTC”) or an associated
person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated
person, director or employee of any investment company, bank, savings and loan association or insurance company, or from engaging
in or continuing any conduct or practice in connection with any such activity; or (ii) engaging in any type of business practice;
or (iii) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any
violation of federal or state securities or federal commodities laws;

 

(f)
He, she, or it has never been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of
any federal or state authority barring, suspending or otherwise limiting for more than 60 days his, her or its right to engage
in any activity described in 8(e)(i) above, or to be associated with persons engaged in any such activity;

 

(g)
He, she or it has never been found by a court of competent jurisdiction in a civil action or by the SEC to have violated any federal,
state, or foreign securities law, where the judgment in such civil action or finding by the SEC has not been subsequently reversed,
suspended or vacated;

 

(h)
He, she or it has never been found by a court of competent jurisdiction in a civil action or by the CFTC to have violated any
federal commodities law, where the judgment in such civil action or finding by the CFTC has not been subsequently reversed, suspended
or vacated;

 

(i)
He, she or it has never been the subject of, or a party to, any federal, state, or foreign judicial or administrative order, judgment,
decree or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (i) any federal ,state
or foreign securities or commodities law or regulation, (ii) any law or regulation respecting financial institutions or insurance
companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money
penalty or temporary or permanent cease-and desist order, or removal or prohibition order or (iii) any law or regulation prohibiting
mail or wire fraud or fraud in connection with any business entity;

 

(j)
He, she or it has never been the subject of, or party to, any sanction or order, not subsequently reversed, suspended or vacated,
or any self-regulatory organization, any registered entity, or any equivalent exchange, association, entity or organization that
has disciplinary authority over its members or persons associated with a member;

 

(k)
He, she or it has never been convicted of any felony or misdemeanor: (i) in connection with the purchase or sale of any security;
(ii) involving the making of any false filing with the SEC; or (iii) arising out of the conduct of the business of an underwriter,
broker, dealer, municipal securities dealer, investment advisor or paid solicitor of purchasers of securities;

 

(l)
He, she or it was never subject to a final order of a state or foreign securities commission (or an agency of officer of a state
performing like functions); a state or foreign authority that supervises or examines banks, savings associations, or credit unions;
a state or foreign insurance commission (or an agency or officer of a state performing like functions); an appropriate federal
or foreign banking agency; the Commodity Futures Trading Commission; or the National Credit Union Administration that is based
on a violation of any law or regulation that prohibits fraudulent, manipulative, or deceptive conduct;

 

(m)
He, she or it has never been subject to any order, judgment or decree of any court of competent jurisdiction, that, at the time
of such sale, restrained or enjoined him from engaging or continuing to engage in any conduct or practice: (i) in connection with
the purchase or sale of any security; (ii) involving the making of any false filing with the SEC or any foreign regulatory agency
with similar functions; or (iii) arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities
dealer, investment adviser or paid solicitor of purchasers of securities;

 

(n)
He, she or it has never been subject to any order of the SEC or any foreign regulatory agency with similar functions that orders
him to cease and desist from committing or causing a future violation of: (i) any scienter-based anti-fraud provision of the foreign
or federal securities laws, including, but not limited to, Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange
Act, and Rule 10b-5 thereunder, and Section 206(1) of the Investment Advisers Act of 1940, as amended (the “Advisers
Act”), or any other rule or regulation thereunder; or (ii) Section 5 of the Securities Act;

 

    4

     

    

 

(o)
He, she or it has never been named as an underwriter in any registration statement or Regulation A offering statement filed with
the SEC that was the subject of a refusal order, stop order, or order suspending the Regulation A exemption, or is, currently,
the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued;

 

(p)
He, she or it has never been subject to a United States Postal Service false representation order, or is currently subject to
a temporary restraining order or preliminary injunction with respect to conduct alleged by the United States Postal Service to
constitute a scheme or device for obtaining money or property through the mail by means of false representations;

 

(q)
He, she or it is not subject to a final order of a state securities commission (or an agency of officer of a state performing
like functions); a state authority that supervises or examines banks, savings associations, or credit unions; a state insurance
commission (or an agency or officer of a state performing like functions); an appropriate federal banking agency; the Commodity
Futures Trading Commission; or the National Credit Union Administration that bars the undersigned from: (i) association with an
entity regulated by such commission, authority, agency or officer; (ii) engaging in the business of securities, insurance or banking;
or (iii) engaging in savings association or credit union activities;

 

(r)
He, she or it is not subject to an order of the SEC entered pursuant to section 15(b) or 15B(c) of the Exchange Act or section
203(e) or 203(f) of the Advisers Act that: (i) suspends or revokes the undersigned’s registration as a broker, dealer, municipal
securities dealer or investment adviser; (ii) places limitations on the activities, functions or operations of, or imposes civil
money penalties on, such person; or (iii) bars the undersigned from being associated with any entity or from participating in
the offering of any penny stock; and

 

(s)
He, she or it has never been suspended or expelled from membership in, or suspended or barred from association with a member of,
a securities self-regulatory organization (e.g., a registered national securities exchange or a registered national or affiliated
securities association) for any act or omission to act constituting conduct inconsistent with just and equitable principles of
trade.

 

11.
 The undersigned has full right and power, without violating any agreement by which he, she or it is bound, to enter into
this letter agreement and to hold the position/title in the Company indicated in the Registration Statement (if applicable).

 

12. The
undersigned hereby waives his, her or its right to exercise redemption rights (in connection with a Business Combination) with
respect to any Ordinary Shares owned or to be owned by the undersigned directly or indirectly, whether purchased prior to the
IPO, in the IPO or in the aftermarket, or whether such Ordinary Shares are underlying the Private Units, and agrees that he, she
or it will not seek redemption with respect to or otherwise sell, such shares in connection with any vote to approve a Business
Combination with respect thereto.

 

13. The
undersigned hereby agrees to not propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association
with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination that
would affect the substance or timing of the Company’s obligation to redeem 100% of the IPO Shares if the Company does not
complete a Business Combination within the time period set forth in the Amended and Restated Memorandum and Articles of Association.

 

14.
 In the event that the Company does not consummate a Business Combination and must liquidate and its remaining net assets
are insufficient to complete such liquidation, the Sponsor agrees to advance such funds necessary to complete such liquidation
and agrees not to seek repayment for such expenses.

 

15.
 Each officer of the Company agrees not to become involved with another publicly listed blank check company with a class
of securities registered under the Exchange Act prior to us announcing an agreement to acquire our initial Business Combination,
or the expiration of the period for us to announce and/or complete our initial Business Combination.

 

    5

     

    

 

16.
 This letter agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York,
without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.
The undersigned hereby (i) agrees that any action, proceeding or claim against him arising out of or relating in any way to this
letter agreement (a “Proceeding”) shall be brought and enforced in the courts of the State of New York
of the United States of America for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive, (ii) waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum
and (iii) irrevocably agrees to appoint Ellenoff Grossman & Schole LLP as agent for the service of process in the State of
New York to receive, for the undersigned and on his behalf, service of process in any Proceeding.

 

17. As
used herein, (i) a “Business Combination” shall mean a share exchange, share reconstruction and amalgamation
with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or any other similar
business combination with one or more businesses or entities; (ii) “Initial Shareholders” shall mean
the Sponsor and any Insider that holds founder shares of the Company; (iii) “Insiders” shall mean all
officers, directors and shareholders of the Company immediately prior to the IPO; (iv) “Insider Shares”
shall mean all of the Ordinary Shares of the Company acquired by an Insider prior to the IPO; (v) “IPO Shares”
shall mean the Ordinary Shares issued in the Company’s IPO; (vi) “Permitted Transferees” shall
mean any transferee that received securities of the Company upon a Transfer in compliance with Section 3(c) herein; (vii)“Private
Units” shall mean (x) the Units purchased in the private placement taking place simultaneously with the consummation
of the Company’s IPO and (y) additional Units that will be purchased in a private placement upon the full or partial exercise
of the underwriters’ over-allotment option for the Company’s IPO; (viii) “Registration Statement”
means the registration statement on Form S-1 filed by the Company with respect to the IPO; (ix) “Transfer”
shall mean the (a) sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase
or otherwise dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position
or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange
Act and the rules and regulations of the Commission promulgated thereunder with respect to, any security, (b) entry into
any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of
any security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (c) public
announcement of any intention to effect any transaction specified in clause (a) or (b); and (x) “Trust Fund”
shall mean the trust fund into which a portion of the net proceeds of the Company’s IPO will be deposited.

 

18.
 Any notice, consent or request to be given in connection with any of the terms or provisions of this letter agreement shall
be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested),
by hand delivery or facsimile transmission.

 

19.
 No party hereto may assign either this letter agreement or any of its rights, interests, or obligations hereunder without
the prior written consent of the other party. Any purported assignment in violation of this paragraph shall be void and ineffectual
and shall not operate to transfer or assign any interest or title to the purported assignee. This letter agreement shall be binding
on the parties hereto and any successors and assigns thereof.

 

20.
 The undersigned acknowledges and understands that the Underwriters and the Company will rely upon the agreements, representations
and warranties set forth herein in proceeding with the IPO.

 

21.
 This letter agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject
matter hereof and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written
or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. This letter
agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision,
except by a written instrument executed by the Company and each officer or director that is the subject of any such change, amendment
modification or waiver.

 

22.
This letter agreement shall terminate on the earlier of (i) the expiration of the Lock-up Periods or (ii) the liquidation of the
Company; provided, however, that this Letter Agreement shall earlier terminate in the event that the IPO
is not consummated and closed by March 31, 2021; provided further that paragraph 3 of this letter agreement shall survive such
liquidation.

[signature
page follows]

 

    6

     

    

 

	 

        
	AMERICAN
    PHYSICIANS LLC
	 	 	 
	 	By:	/s/
    Xiaoping Becky Zhang
	 	 	Name: 	Xiaoping
    Becky Zhang
	 	 	Title:
     	Managing
    Member

 

	 	/s/
    Kevin Chen 
	 	Kevin
    Chen

 

	 	/s/
    Christine Zhao
	 	Christine
    Zhao

 

	 	/s/
    Bob Ai
	 	Bob
    Ai

 

	 	/s/
    Gang Li 
	 	Gang
    Li

 

	 	/s/
    Jiuji Yan 
	 	Jiuji
    Yan

 

Acknowledged
and Agreed:

 

EDOC
ACQUISITION CORP.

 

	By: 	/s/
    Kevin Chen	 
	 	Name: 	Kevin
    Chen	 
	 	Title:
	Chief
                                         Executive Officer

        

        

 

 

[Signature
Page to the Insider Letter]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]